Fingerprint
Dive into the research topics of 'EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically